The actual empirical case for decentralized research
Decentralized clinical trials aim to move some study activities into homes, local clinics and digital environments. FDA guidance describes these methods as possible research delivery options. Their value is plausible: reducing travel and involving community clinicians may reach people excluded by geographic barriers. The proposition that decentralization consistently lowers cost or increases enrollment, however, requires comparative evidence. F18P04
A systematic review published in 2021 included 45 trials for quantitative analysis and 117 documents qualitatively, but design and reporting heterogeneity prevented meta-analysis of the primary recruitment outcome. The authors reported insufficient evidence to identify which decentralized methods reliably improve recruitment, retention or total cost. This is a scientifically important constraint on any claim that an online platform automatically solves access. P01
A later review identified 53 papers and reported wide variation in remote consent, outcome collection and intervention type. Challenges included retention and selection bias. A 2026 ethics review synthesized 32 articles and grouped recurring concerns into consent, equity, confidentiality, safety, scientific validity and oversight. Such reviews support studying decentralized models carefully, not claiming that any one version has proven superior. P03P05
FDA's 2025 E6(R3) guidance supports quality by design and proportionate approaches for contemporary clinical research. That framework makes it reasonable to propose a small-sponsor research-quality service, standardized records and monitored decentralized methods. It is not evidence that reducing oversight would improve participant outcomes. F19
The evidence problem in N-of-1 and individualized studies
An N-of-1 study may use structured, repeated comparisons within one person to estimate an individualized intervention effect. It can be more informative than an uncontrolled anecdote when design, blinding, washout, outcome selection and statistical analysis are suitable. But nonrandomized self-tracking without an appropriate counterfactual cannot reliably isolate intervention effects from time trends, expectation, regression to the mean or co-interventions. P08P09
A 2023 systematic review assessed 115 published N-of-1 medical studies against defined standards and found that only four met all evaluated evidence requirements. The authors identified insufficient effect-size reporting, inadequate raw data access and common analytical mistakes. That finding argues for a public methods library, not for an uncritical claim that independently collected observations are already clinical-grade evidence. P07
Design choices matter: prospectively specified outcomes, random allocation where feasible, measurable adherence, an acceptable washout, autocorrelation-aware analysis, uncertainty intervals, adverse-event capture and shareable code determine whether a result can be learned from. The proposed policy framework should fund independent design assistance before intervention begins. P07P08
Individualized research also creates an ethical tension between helping a particular participant now and producing generalizable scientific knowledge for others. An academic framework should clearly identify which purpose governs a protocol and disclose if different requirements apply. P10
Platform trials and shared protocols
Adaptive or platform trials can evaluate multiple hypotheses through a master protocol, possibly adding or removing study arms under predeclared rules. This can promote reuse of governance and operations, though it does not eliminate methodological or reporting duties. A review of 189 platform trials found substantial variability in protocol availability and statistical transparency. P06
For a community research commons, the scientific question is whether a shared template can improve compliance and data comparability without forcing heterogeneous projects into a single unfit design. Shared data dictionaries, versioned protocols and central statistical review can reduce fragmentation. They cannot substitute for a prespecified estimand or product-specific risk analysis.
Research registries may create valuable descriptive evidence and opportunities for hypothesis generation. They should not automatically be sold as substitutes for randomized comparison, validated endpoints or appropriate causal inference. Legislators should fund evidence-grade infrastructure rather than reward only large submission counts.
Reproducibility, publication bias and the public interest
A serious research-freedom initiative should make negative findings discoverable, not only successful or enthusiastic case reports. Registration before data collection, transparent outcome definitions, versioned analysis plans, and a visible record of protocol changes can make independent work more interpretable.
An accessible science repository should record product provenance, measurement methods, missing data, adverse events and the limits of claims. Depositing privacy-preserving aggregates and analytic code can help outside reviewers identify inconsistencies. Access to underlying sensitive data requires separately governed consent; open science does not mean public exposure of genomic or health records. F15P06P07
The most defensible scientific promise is not that community-led research will prove a favored therapy works. It is that accountable participation can generate better-framed questions, usable negative results, independent replication and transparent data, with clear distinctions among mechanism, observational association and causal evidence.
What Congress should fund as evaluation
A pilot should prespecify primary measures such as the proportion of complete research proposals reaching a timely classification decision, median cost of independent protocol preparation, representation of geographically isolated participants, validated participant comprehension and completeness of safety follow-up.
Secondary measures could include public release of negative results, completeness of adverse-event reports, rate of protocol deviation, privacy complaints, data-access turnaround, successful withdrawal of future permissions and participant trust scores. Comparisons to similar nonpilot projects require matched baseline characteristics and explicit adjustment for selection bias.
Do not use number of signers, traffic, revenue or volume of claimed discoveries as a scientific outcome. Those measures may help the civic campaign, but they cannot substitute for study quality or substantive policy performance. The initiative should insist on evaluation methods rigorous enough to justify continuation or amendment.